Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Strategic Partnership Agreement with Norwich Capital Limited
First Patient Dosed in Ground-Breaking First-in-Human mRNA Trial for Knee Osteoarthritis
Rocky H. Kato Appointed President of Nano Holdings US, LLC
Neil W. Gibson Appointed as Chairman of Nano Holdings US, LLC
Accelerated Integration of Experienced Executive Talent -Dr. Yasunori Yamaguchi Appointed as Chief Business Development Officer
NANO MRNA Co., Ltd. Announces Strategic Alliance with SBI Securities and SBI Shinsei Corporate Investment
RUNX1 mRNA, a disease modifier for knee osteoarthritis: Study plan Approval for initiation of Phase 1 clinical trial
RUNX1 mRNA, a disease modifier for knee osteoarthritis : Study plan submitted for initiation of Phase 1 clinical trial
TUG1 ASO for glioblastoma : Phase 1 clinical trial reaches final dosing level
[Delayed] We will exhibit at the Japan Pavilion during the 2025 BIO International Convention